NO2015002I2 - Ataluren (3-[5-(2-fluorfenyl)-[ 1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav - Google Patents

Ataluren (3-[5-(2-fluorfenyl)-[ 1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav

Info

Publication number
NO2015002I2
NO2015002I2 NO2015002C NO2015002C NO2015002I2 NO 2015002 I2 NO2015002 I2 NO 2015002I2 NO 2015002 C NO2015002 C NO 2015002C NO 2015002 C NO2015002 C NO 2015002C NO 2015002 I2 NO2015002 I2 NO 2015002I2
Authority
NO
Norway
Prior art keywords
ataluren
oxadiazol
solvates
fluorophenyl
pharmaceutically acceptable
Prior art date
Application number
NO2015002C
Other languages
English (en)
Other versions
NO2015002I1 (no
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of NO2015002I2 publication Critical patent/NO2015002I2/no
Publication of NO2015002I1 publication Critical patent/NO2015002I1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
NO2015002C 2003-04-11 2015-02-03 Ataluren (3-[5-(2-fluorfenyl)-[1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav NO2015002I1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46198803P 2003-04-11 2003-04-11
PCT/US2004/011106 WO2004091502A2 (en) 2003-04-11 2004-04-09 1,2,4-oxadiazole benzoic acid compounds

Publications (2)

Publication Number Publication Date
NO2015002I2 true NO2015002I2 (no) 2015-02-03
NO2015002I1 NO2015002I1 (no) 2015-02-16

Family

ID=33299886

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20055314A NO332843B1 (no) 2003-04-11 2005-11-10 1,2,4-oksadiazolbenzosyreforbindelser, anvendelse derav og farmasoytisk sammensetning inneholdende en slik forbindelse.
NO2015002C NO2015002I1 (no) 2003-04-11 2015-02-03 Ataluren (3-[5-(2-fluorfenyl)-[1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20055314A NO332843B1 (no) 2003-04-11 2005-11-10 1,2,4-oksadiazolbenzosyreforbindelser, anvendelse derav og farmasoytisk sammensetning inneholdende en slik forbindelse.

Country Status (30)

Country Link
US (17) US6992096B2 (no)
EP (9) EP3178816A1 (no)
JP (2) JP4851933B2 (no)
KR (1) KR101134188B1 (no)
CN (2) CN1802360B (no)
AU (1) AU2004229487B9 (no)
BE (1) BE2015C025I2 (no)
BR (1) BRPI0409319B8 (no)
CA (1) CA2521992C (no)
CR (1) CR8086A (no)
CY (6) CY1115870T1 (no)
DK (7) DK1618098T3 (no)
EA (1) EA009120B1 (no)
ES (7) ES2528195T3 (no)
FR (1) FR15C0030I2 (no)
HK (4) HK1093979A1 (no)
HU (7) HUE047569T2 (no)
IL (2) IL171343A (no)
LU (1) LU92698I2 (no)
MA (1) MA27802A1 (no)
MX (1) MXPA05010747A (no)
NO (2) NO332843B1 (no)
NZ (1) NZ543263A (no)
PL (7) PL3345895T3 (no)
PT (7) PT1618098E (no)
SI (7) SI1618098T1 (no)
TR (1) TR201706226T4 (no)
UA (1) UA84420C2 (no)
WO (1) WO2004091502A2 (no)
ZA (1) ZA200508298B (no)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
WO2004001010A2 (en) * 2002-06-21 2003-12-31 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
WO2004010106A2 (en) * 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
MXPA05010747A (es) 2003-04-11 2006-05-25 Ptc Therapeutics Inc Compuestos de acido 1,2,4-oxadiazolbenzoico y su uso para la supresion sin sentido y el tratamiento de enfermedades.
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
CA2582885A1 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases
AU2012238226B2 (en) * 2005-04-08 2015-05-14 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
ES2390804T3 (es) 2005-04-08 2012-11-16 Ptc Therapeutics, Inc. Composiciones de un 1,2,4-oxadiazol oralmente activo para terapia de supresión de la mutación sin sentido
CN100378084C (zh) * 2005-08-01 2008-04-02 安徽大学 2,5-二芳基取代基-1,3,4-噁二唑衍生物及其合成方法、用途
JP5265384B2 (ja) * 2006-02-09 2013-08-14 エンゾン ファーマスーティカルズ インコーポレイテッド 乳癌、結腸直腸癌、膵臓癌、卵巣癌及び肺癌の治療のための７−エチル−１０−ヒドロキシカンプトセシンのマルチアーム・ポリマー複合体
RU2462246C2 (ru) * 2006-03-30 2012-09-27 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы получения функционального белка из днк, имеющей нонсенс-мутацию, и лечения нарушений, ассоциированных с ней
WO2007116229A1 (en) * 2006-04-06 2007-10-18 Prosidion Limited Heterocyclic gpcr agonists
SI3091011T1 (en) 2006-04-07 2018-06-29 Vertex Pharmaceuticals Incorporated Modulators of ATP conveyor belt conveyors
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) * 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
WO2007130499A2 (en) * 2006-05-01 2007-11-15 Virobay, Inc. Antiviral agents
NZ575511A (en) * 2006-09-08 2012-02-24 Ptc Therapeutics Inc Processes for the preparation of 1,2,4-oxadiazole benzoic acids
WO2008130370A1 (en) * 2006-09-25 2008-10-30 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
HUE028503T2 (en) 2006-09-25 2016-12-28 Ptc Therapeutics Inc Crystalline Forms of 3- [5- (2-Fluorophenyl) - [1,2,4] oxadiazol-3-yl] benzoic acid
AU2016262645B2 (en) * 2006-10-12 2018-05-17 Ptc Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
AU2013219243B2 (en) * 2006-10-12 2016-09-08 Ptc Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
CL2007002923A1 (es) 2006-10-12 2008-06-06 Ptc Therapeutics Inc Soc Organ Metodo para el tratamiento, prevencion o manejo de una enfermedad asociada con una mutacion sin sentido tal como cancer, diabetes o enfermedad pulmonar, que consiste en administrar a un paciente una cantidad efectiva de acido 3-[5-(2-fluoro-fenil)-[1
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
BRPI0720043A2 (pt) * 2006-12-15 2014-01-07 Abbott Lab Composto oxadiazol
US20110207704A1 (en) * 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CN101668732A (zh) * 2007-04-02 2010-03-10 同一世界健康研究院 Cftr抑制剂化合物及其用途
CN101965344B (zh) * 2007-06-22 2013-03-06 弗·哈夫曼-拉罗切有限公司 异*唑-咪唑衍生物
WO2009013477A1 (en) * 2007-07-23 2009-01-29 Summit Corporation Plc Compounds for treating duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
ES2617957T3 (es) 2007-08-03 2017-06-20 Summit (Oxford) Limited Combinaciones farmacológicas para el tratamiento de la distrofia muscular de Duchenne
PL2786994T3 (pl) 2007-08-13 2018-04-30 Monsanto Technology Llc Kompozycje i sposoby zwalczania nicieni
US8202865B2 (en) * 2007-10-04 2012-06-19 Merck Serono Sa Oxadiazole derivatives
US8404676B2 (en) 2007-10-04 2013-03-26 Merck Serono Sa Oxadiazole diaryl compounds
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
SI2217572T1 (sl) 2007-11-16 2014-05-30 Vertex Pharmaceuticals Incorporated Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto
JP5645217B2 (ja) 2007-12-07 2014-12-24 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー ５，６−二置換オキシンドール誘導体およびバソプレッシン依存性疾患を治療するためのこれらの使用
MX2010006202A (es) 2007-12-07 2011-03-04 Abbott Gmbh & Co Kg Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
EP3683218A1 (en) 2007-12-07 2020-07-22 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
BRPI0820668A2 (pt) * 2007-12-07 2017-08-22 Abbott Gmbh & Co Kg Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
KR20100110834A (ko) * 2007-12-21 2010-10-13 메르크 세로노 에스. 에이. 트리아졸 옥사다이아졸 유도체
AU2008342122B2 (en) * 2007-12-25 2012-06-14 Kissei Pharmaceutical Co., Ltd. Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition
WO2009100438A2 (en) 2008-02-07 2009-08-13 Massachusetts Eye & Ear Infirmary Compounds that enhance atoh-1 expression
PL2615085T3 (pl) 2008-03-31 2016-02-29 Vertex Pharma Pochodne pirydynowe jako modulatory CFTR
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20100099677A1 (en) * 2008-04-21 2010-04-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Thiazole Derivatives
WO2009131957A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20090264481A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Oxadiazole Derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
WO2009131956A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazole derivatives
AU2009266098B2 (en) * 2008-06-09 2015-01-22 Ludwig-Maximilians-Universitat Munchen New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
MX2010014569A (es) * 2008-06-24 2011-03-29 Irm Llc Compuestos y metodos para modular los receptores acoplados con proteina-g.
EP2341776A4 (en) * 2008-09-19 2012-05-30 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES
US8017555B2 (en) 2009-02-10 2011-09-13 Divergence, Inc. Compositions and methods for controlling nematodes
JP5620129B2 (ja) * 2009-03-19 2014-11-05 富士フイルム株式会社 光学フィルム、位相差板、楕円偏光板、液晶表示装置、及び化合物
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP2251437B1 (en) 2009-05-13 2013-12-04 Hannelore Breitenbach-Koller Method for identifying compounds that control the translational activity of ribosomal proteins in differential mRNA expression
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
AR076984A1 (es) 2009-06-08 2011-07-20 Merck Serono Sa Derivados de pirazol oxadiazol
US9849146B2 (en) * 2009-07-20 2017-12-26 Rutgers, The State University Of New Jersey Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
BR122020024226B1 (pt) * 2009-08-05 2021-09-08 International Paper Company Processo para preparar uma folha de polpa fofa
WO2011060392A1 (en) 2009-11-13 2011-05-19 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
KR101781233B1 (ko) * 2009-11-13 2017-09-22 셀진 인터내셔널 Ii 에스에이알엘 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN109081804B (zh) 2010-03-25 2021-12-10 弗特克斯药品有限公司 环丙烷甲酰胺的固体形式
NZ602795A (en) 2010-04-07 2015-01-30 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CA2795804C (en) 2010-04-07 2021-10-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
EP3381899B1 (en) 2010-04-22 2021-01-06 Vertex Pharmaceuticals Incorporated Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
DK2600865T3 (en) 2010-08-05 2019-02-25 Univ Lille Compound for the treatment of nonsense mutation-mediated diseases as well as pharmaceutical composition comprising this compound
RU2013112937A (ru) 2010-08-23 2014-09-27 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции (r)-1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)-n-(2, 3-дигидроксипропил)-6-фтор-2-(1-гидрокси-2-метилпропан-2-ил)-1н-индол-5-ил)циклопропанкарбоксамида и их применение
JP6129159B2 (ja) 2011-05-13 2017-05-17 レセプトス エルエルシー 選択的複素環式スフィンゴシン１−リン酸受容体モジュレーター
EP2717855A4 (en) 2011-06-07 2014-11-12 Parion Sciences Inc PROCESSING METHODS
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
US20140094465A1 (en) * 2011-06-10 2014-04-03 N30 Pharmaceuticals, Inc. Compounds as S-Nitrosoglutathione Reductase Inhibitors
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
KR101314488B1 (ko) * 2011-09-08 2013-10-07 중앙대학교 산학협력단 신경줄기세포 분화조절제용 신규 옥사디아졸 유도체 및 이의 의학적 용도
ME02650B (me) 2011-11-08 2017-06-20 Vertex Pharma Modulatori atp- vezujućih kasetnih transportera
RU2644723C2 (ru) 2012-01-25 2018-02-13 Вертекс Фармасьютикалз Инкорпорейтед Препараты 3-(6-(1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
US9598395B2 (en) 2012-03-23 2017-03-21 The Regents Of The University Of California Premature-termination-codons readthrough compounds
EA032734B1 (ru) 2012-05-29 2019-07-31 Парион Сайэнс, Инк. Дендримероподобные аминоамиды, обладающие активностью блокаторов натриевых каналов, для лечения сухости глаз и других заболеваний слизистых оболочек
DK2867230T3 (da) * 2012-07-02 2020-04-14 Monsanto Technology Llc Fremgangsmåde til fremstilling af 3,5-disubstitueret 1,2,4-oxadiazoler
AR092857A1 (es) 2012-07-16 2015-05-06 Vertex Pharma Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
EP2914248B2 (en) 2012-11-02 2023-10-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cftr mediated diseases
JP6076498B2 (ja) 2012-12-13 2017-02-08 ノバルティス アーゲー ナンセンス突然変異抑制剤としてのピリミド［４，５−ｂ］キノリン−４，５（３ｈ，１０ｈ）−ジオン
CA2896686A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
PL2931713T3 (pl) 2012-12-17 2017-06-30 Parion Sciences, Inc. Chloro-pirazynowe pochodne karboksyamidowe do leczenia chorób, którym sprzyja niedostateczne nawilżenie błon śluzowych
RU2671976C2 (ru) 2012-12-17 2018-11-08 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
CN112979575A (zh) * 2014-03-06 2021-06-18 Ptc医疗公司 1,2,4-噁二唑苯甲酸的药物组合物和盐
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
BR112016023422A8 (pt) 2014-04-15 2021-07-20 Vertex Pharma dispersão seca por spray, composição farmacêutica e seus usos, kit e comprimido
ES2743184T3 (es) 2014-06-03 2020-02-18 Novartis Ag Derivados de pirimido[4,5-b]quinolin-4,5(3H,10H)-diona como supresores de mutaciones finalizadoras
AU2015270125B2 (en) 2014-06-03 2017-10-19 Novartis Ag Naphthyridinedione derivatives
US9884862B2 (en) 2014-06-03 2018-02-06 Novartis Ag Pyridopyrimidinedione derivatives
CN105461650B (zh) * 2014-09-12 2018-04-13 杭州普晒医药科技有限公司 一种噁二唑化合物的溶剂化物及其制备方法
EP4159717A1 (en) 2014-10-06 2023-04-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN104292180A (zh) * 2014-10-12 2015-01-21 湖南华腾制药有限公司 一种恶二唑衍生物的制备方法
US10174012B2 (en) 2014-11-04 2019-01-08 The University Of Kansas LKB1-AMPK activators for therapeutic use in polycystic kidney disease
WO2016073545A1 (en) * 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016097004A1 (en) 2014-12-17 2016-06-23 King's College London BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS
CN106316885B (zh) * 2015-07-03 2019-02-12 普济生物科技（台州）有限公司 一种3-[5-(2-氟苯基)-1,2,4-噁二唑-3-基]苯甲酸的制备方法
WO2017075312A1 (en) 2015-10-30 2017-05-04 Ptc Therapeutics, Inc. Methods for treating epilepsy
PT3377476T (pt) * 2015-11-16 2022-12-29 Ptc Therapeutics Inc Análogos enriquecidos com isótopo de hidrogénio de compostos de ácido 1,2,4-oxadiazole benzoico, composições e suas utilizações
JP2019505579A (ja) 2015-12-23 2019-02-28 ムーンショット ファーマ エルエルシー 免疫応答を誘導するための方法
TW201808922A (zh) * 2016-06-20 2018-03-16 台灣神隆股份有限公司 製備阿塔魯仁及其中間體的方法
GB201610867D0 (en) 2016-06-22 2016-08-03 King's College London Crystalline forms of a therapeutic compound and processes for their preparation
CN106279057B (zh) * 2016-08-15 2022-04-15 广州明药科技有限公司 Ataluren的合成方法
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
WO2018050706A1 (en) 2016-09-13 2018-03-22 Marco Cipolli Method of treatment of shwachman-diamond syndrome
US11439623B2 (en) 2017-04-04 2022-09-13 Case Western Reserve University Method of modulating ribonucleotide reductase
US11654135B2 (en) 2017-06-22 2023-05-23 Moonshot Pharma Llc Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors
US11795196B2 (en) 2017-12-15 2023-10-24 Stealth Biotherapeutics Inc. Mitochondria-targeting peptides
WO2020078894A1 (en) 2018-10-15 2020-04-23 Academisch Medisch Centrum Oncotherapeutic combinations
WO2020138935A1 (ko) * 2018-12-27 2020-07-02 제이투에이치바이오텍 주식회사 근이영양증의 치료 또는 예방에 유용한 화합물 및 이들의 의약 용도의 치료, 개선 또는 예방용 유도체
CN110987847B (zh) * 2019-12-11 2021-02-19 苏州今蓝纳米科技有限公司 1,3,4-噁二唑衍生物在检测酸以及数据加密和储存中的应用
CN111675672A (zh) * 2020-05-12 2020-09-18 石家庄市度智医药科技有限公司 一种制备阿塔鲁伦的方法
CN113045510B (zh) * 2021-03-31 2022-05-27 北京大学生命科学华东产业研究院 一种阿塔鲁伦的制备方法
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
US11932632B1 (en) 2023-10-13 2024-03-19 King Faisal University N'-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzo[d][1,3]dioxole-5 carboximidamide as an antimicrobial compound
US11958814B1 (en) 2023-11-02 2024-04-16 King Faisal University 3-(4-nitrophenyl)-5-((2-isopropyl-5-methylphenoxy)methyl)-1,2,4-oxadiazole as an anti-cancer and antimicrobial compound

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291628A (no) 1962-04-17
US3325446A (en) * 1964-04-17 1967-06-13 Allied Chem Stabilized halogen-containing olefin polymer compositions and stabilizers therefor
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4022901A (en) 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
JPS51143669A (en) 1975-06-06 1976-12-10 Takeda Chem Ind Ltd A process for preparing 1,2,4- oxadiazole derivatives
US4016170A (en) * 1975-07-28 1977-04-05 Sandoz, Inc. Oxadiazolyl benzamides
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4166732A (en) * 1977-05-12 1979-09-04 Monsanto Company Oxadiazol-5-yl-benzoates
US4135910A (en) 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
US4165910A (en) * 1977-10-25 1979-08-28 Bunker Ramo Corporation Electrical connector
AU531759B2 (en) 1978-04-17 1983-09-08 Ici Ltd. Electrostatic spraying
US4268299A (en) * 1978-08-17 1981-05-19 Monsanto Company Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates
US4210762A (en) * 1978-08-17 1980-07-01 Monsanto Company 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates
EP0036711B1 (en) * 1980-03-22 1985-12-04 Fbc Limited Pesticidal heterocyclic compounds, processes for preparing them, compositions containing them, and their use
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
GB9225098D0 (en) 1992-12-01 1993-01-20 Coffee Ronald A Charged droplet spray mixer
GB9226717D0 (en) 1992-12-22 1993-02-17 Coffee Ronald A Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DE4320801A1 (de) 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
US5484944A (en) * 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
GB9406171D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9406255D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
TW343965B (en) 1994-03-30 1998-11-01 Hoffmann La Roche Novel mono- and bicyclic DNA gyrase inhibitors
GB9410658D0 (en) 1994-05-27 1994-07-13 Electrosols Ltd Dispensing device
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6071700A (en) 1995-01-20 2000-06-06 University Of Massachusetts Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions
DE69605025T2 (de) 1995-03-14 2000-07-20 Siemens Ag Ultraschallzerstäuber mit abnehmbarer präzisionsdosiereinheit
WO1996028205A1 (en) 1995-03-14 1996-09-19 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosing unit
SK30198A3 (en) 1995-09-07 1998-08-05 Novartis Ag Substituted phosphinic compounds and their use as pharmaceuticals
US6251941B1 (en) 1996-04-19 2001-06-26 Sloan-Kettering Institute For Cancer Research Use of inhaled retinoids in the prevention of cancer
WO1997041105A1 (fr) * 1996-04-26 1997-11-06 Nippon Soda Co., Ltd. Nouveaux derives de benzene a substitution heterocycle et herbicides
DE19620041A1 (de) * 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US6034106A (en) * 1996-06-07 2000-03-07 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity
CA2257206A1 (en) 1996-06-07 1997-12-11 Gui-Bai Liang Oxadiazole benzenesulfonamides as selective .beta.3 agonists for the treatment of diabetes and obesity
DE19626318A1 (de) * 1996-07-01 1998-01-08 Basf Ag Farbstoffmischungen, enthaltend Polyazofarbstoffe
ZA98371B (en) 1997-01-31 1999-07-16 Du Pont Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides.
JP4578580B2 (ja) * 1997-04-07 2010-11-10 ジョージタウン ユニヴァーシティー コカインの類似化合物
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
US5954047A (en) 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
AU9647998A (en) * 1997-10-27 1999-05-17 Nippon Soda Co., Ltd. Novel benzoylpyrazole derivatives and herbicides
SK13632000A3 (sk) 1998-03-16 2001-03-12 Inhale Therapeutic Systems, Inc. Spôsob podávania aktívnej látky do pľúc ľudského pacienta a zariadenie na jeho vykonávanie
WO1999054317A1 (en) 1998-04-23 1999-10-28 Cortech Inc. Cysteine protease inhibitors
CN1329609A (zh) 1998-10-08 2002-01-02 史密丝克莱恩比彻姆有限公司 用作多巴胺d3受体调制剂(精神抑制药)的四氢苯并氮杂䓬衍生物
CA2346396C (en) 1998-10-09 2009-04-28 Janssen Pharmaceutica N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
AU1455500A (en) 1998-10-29 2000-05-22 Trega Biosciences, Inc. Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof
TR200101869T2 (tr) * 1998-12-23 2002-01-21 Smithkline Beecham Corporation Proteaz İnhibitörleri.
WO2000058280A1 (fr) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Derives de sulfonamide carbocyclique
AU3196100A (en) 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
AU3196200A (en) 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Beta-amino acid derivatives
EP1183229B1 (en) 1999-05-17 2005-10-26 Novo Nordisk A/S Glucagon antagonists/inverse agonists
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6458538B1 (en) 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
EP1268494A1 (en) * 2000-03-22 2003-01-02 Merck Frosst Canada &amp; Co. Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
WO2001083464A1 (fr) * 2000-04-21 2001-11-08 Shionogi & Co., Ltd. Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaire
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
CA2409827C (en) 2000-05-22 2010-06-01 Aventis Pharmaceuticals Products Inc. Arylmethylamine derivatives for use as tryptase inhibitors
CN1328143A (zh) 2000-06-12 2001-12-26 上海博德基因开发有限公司 一种新的多肽——人甲基化－dna－蛋白－半胱氨酸甲基转移酶13和编码这种多肽的多核苷酸
JP2002105073A (ja) 2000-09-27 2002-04-10 Shionogi & Co Ltd 新規マトリックスメタロプロテアーゼ阻害剤
AUPR362001A0 (en) 2001-03-08 2001-04-05 Fujisawa Pharmaceutical Co., Ltd. New compound
CA2342432A1 (en) 2001-03-28 2002-09-28 Christopher Norbert Johnson Novel compound
GB0108102D0 (en) * 2001-03-30 2001-05-23 Pfizer Ltd Compounds
BR0209054A (pt) 2001-04-19 2004-04-20 Bayer Ag Arilsulfonamidas como agentes antivirais
AU2002313633B2 (en) 2001-06-08 2007-03-01 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
JP2003081832A (ja) * 2001-06-26 2003-03-19 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
US20040132726A1 (en) 2002-08-09 2004-07-08 Astrazeneca Ab And Nps Pharmaceuticals, Inc. New compounds
CA2495179A1 (en) 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
AU2004224082A1 (en) 2003-03-28 2004-10-07 Pfizer Products Inc. 1,2,4-substitute 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as CETP inhibitors for the treatment of atherosclerosis and obesity
MXPA05010747A (es) * 2003-04-11 2006-05-25 Ptc Therapeutics Inc Compuestos de acido 1,2,4-oxadiazolbenzoico y su uso para la supresion sin sentido y el tratamiento de enfermedades.
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
WO2005060961A2 (en) 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
CA2582885A1 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases
ES2390804T3 (es) * 2005-04-08 2012-11-16 Ptc Therapeutics, Inc. Composiciones de un 1,2,4-oxadiazol oralmente activo para terapia de supresión de la mutación sin sentido
RU2462246C2 (ru) 2006-03-30 2012-09-27 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы получения функционального белка из днк, имеющей нонсенс-мутацию, и лечения нарушений, ассоциированных с ней
WO2007123848A2 (en) 2006-04-19 2007-11-01 Brown University Therapeutic compositions containing modified class i slrp proteins
NZ575511A (en) 2006-09-08 2012-02-24 Ptc Therapeutics Inc Processes for the preparation of 1,2,4-oxadiazole benzoic acids
HUE028503T2 (en) 2006-09-25 2016-12-28 Ptc Therapeutics Inc Crystalline Forms of 3- [5- (2-Fluorophenyl) - [1,2,4] oxadiazol-3-yl] benzoic acid
CL2007002923A1 (es) 2006-10-12 2008-06-06 Ptc Therapeutics Inc Soc Organ Metodo para el tratamiento, prevencion o manejo de una enfermedad asociada con una mutacion sin sentido tal como cancer, diabetes o enfermedad pulmonar, que consiste en administrar a un paciente una cantidad efectiva de acido 3-[5-(2-fluoro-fenil)-[1
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110177999A1 (en) 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
US8202865B2 (en) 2007-10-04 2012-06-19 Merck Serono Sa Oxadiazole derivatives
DK2203173T3 (en) 2007-10-26 2016-02-29 Academisch Ziekenhuis Leiden Materials and methods for prevention of muscle diseases
WO2009079562A2 (en) 2007-12-17 2009-06-25 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
MX2010014569A (es) 2008-06-24 2011-03-29 Irm Llc Compuestos y metodos para modular los receptores acoplados con proteina-g.
WO2010042553A1 (en) 2008-10-07 2010-04-15 Mpex Pharmaceuticals, Inc. Aerosol fluoroquinolone formulations for improved pharmacokinetics
RU2398770C1 (ru) 2009-03-27 2010-09-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота

Also Published As

Publication number Publication date
ES2887054T3 (es) 2021-12-21
US7683082B2 (en) 2010-03-23
FR15C0030I1 (no) 2015-05-22
HUE055434T2 (hu) 2021-11-29
US20130289007A1 (en) 2013-10-31
MA27802A1 (fr) 2006-03-01
CY2015017I1 (el) 2016-06-22
EP3549936B1 (en) 2021-06-02
US20120277234A1 (en) 2012-11-01
WO2004091502A2 (en) 2004-10-28
CN1802360A (zh) 2006-07-12
SI3103800T1 (sl) 2018-10-30
NO20055314D0 (no) 2005-11-10
NO332843B1 (no) 2013-01-21
JP5436500B2 (ja) 2014-03-05
US20140301978A1 (en) 2014-10-09
EP2910551B1 (en) 2017-02-15
BRPI0409319B1 (pt) 2019-11-12
PL1618098T3 (pl) 2015-04-30
SI2910551T1 (sl) 2017-07-31
EP3345895A1 (en) 2018-07-11
US20060148864A1 (en) 2006-07-06
IL225161A (en) 2014-03-31
US7202262B2 (en) 2007-04-10
ES2770035T3 (es) 2020-06-30
KR20060009838A (ko) 2006-02-01
HUE039026T2 (hu) 2018-12-28
EP4101846B1 (en) 2023-08-02
EP3345895B1 (en) 2019-12-04
BRPI0409319A (pt) 2006-04-25
DK3632902T3 (da) 2021-09-13
US20060148863A1 (en) 2006-07-06
AU2004229487B2 (en) 2010-05-20
LU92698I2 (fr) 2015-06-22
HUS1500021I1 (hu) 2017-04-28
SI3345895T1 (sl) 2020-03-31
IL171343A (en) 2013-06-27
BE2015C025I2 (no) 2023-08-09
ES2881198T3 (es) 2021-11-29
DK1618098T3 (en) 2015-01-12
US8227494B2 (en) 2012-07-24
HUE059464T2 (hu) 2022-11-28
PL3549936T3 (pl) 2021-11-08
PT3889142T (pt) 2022-08-22
KR101134188B1 (ko) 2012-04-12
US20100121070A1 (en) 2010-05-13
EA200501601A1 (ru) 2006-06-30
EP3632902B1 (en) 2021-07-14
BRPI0409319B8 (pt) 2021-05-25
DK2910551T3 (en) 2017-05-15
CA2521992A1 (en) 2004-10-28
PT2910551T (pt) 2017-05-22
PT3103800T (pt) 2018-07-27
US8486982B2 (en) 2013-07-16
US8796322B2 (en) 2014-08-05
US20100168109A1 (en) 2010-07-01
US20180092887A1 (en) 2018-04-05
EP3549936A1 (en) 2019-10-09
DK3345895T3 (da) 2020-02-03
CY1124464T1 (el) 2022-07-22
EP1618098A2 (en) 2006-01-25
US20150148346A1 (en) 2015-05-28
EP3889142B1 (en) 2022-06-15
EP3103800A1 (en) 2016-12-14
PT3632902T (pt) 2021-09-15
US8163782B2 (en) 2012-04-24
JP2011251981A (ja) 2011-12-15
CA2521992C (en) 2013-02-05
JP2006522826A (ja) 2006-10-05
UA84420C2 (ru) 2008-10-27
CY2015017I2 (el) 2016-06-22
US7772259B2 (en) 2010-08-10
US7419991B2 (en) 2008-09-02
CN104056278B (zh) 2017-01-18
CN104056278A (zh) 2014-09-24
PL3632902T3 (pl) 2021-12-20
US8017636B2 (en) 2011-09-13
US20070161687A1 (en) 2007-07-12
US7304080B2 (en) 2007-12-04
PL3103800T3 (pl) 2018-11-30
PL2910551T3 (pl) 2017-09-29
SI3549936T1 (sl) 2021-09-30
NO20055314L (no) 2006-01-04
NO2015002I1 (no) 2015-02-16
WO2004091502A8 (en) 2005-11-24
ES2624610T3 (es) 2017-07-17
EP3889142A1 (en) 2021-10-06
US20110311486A1 (en) 2011-12-22
NZ543263A (en) 2008-12-24
MXPA05010747A (es) 2006-05-25
CY1120446T1 (el) 2019-07-10
CN1802360B (zh) 2014-05-07
EP3103800B1 (en) 2018-06-13
US9205088B2 (en) 2015-12-08
PT1618098E (pt) 2015-02-10
CY1115870T1 (el) 2016-06-22
AU2004229487B9 (en) 2010-06-10
PT3345895T (pt) 2020-01-29
ZA200508298B (en) 2007-01-31
EP3178816A1 (en) 2017-06-14
DK3103800T3 (en) 2018-07-30
SI3632902T1 (sl) 2022-01-31
PL3889142T3 (pl) 2022-09-26
US20120178080A1 (en) 2012-07-12
US20060035943A1 (en) 2006-02-16
HK1214253A1 (zh) 2016-07-22
EA009120B1 (ru) 2007-10-26
JP4851933B2 (ja) 2012-01-11
HUE055056T2 (hu) 2021-10-28
SI3889142T1 (sl) 2022-10-28
CY1122659T1 (el) 2020-10-14
CY1119001T1 (el) 2018-01-10
EP1618098A4 (en) 2008-07-16
EP3632902A1 (en) 2020-04-08
US20050164973A1 (en) 2005-07-28
EP2910551A1 (en) 2015-08-26
DK3549936T3 (da) 2021-07-12
HK1257517A1 (zh) 2019-10-25
WO2004091502A3 (en) 2004-12-29
FR15C0030I2 (fr) 2015-07-24
HUE047569T2 (hu) 2020-04-28
US20160081988A1 (en) 2016-03-24
TR201706226T4 (tr) 2018-06-21
PT3549936T (pt) 2021-07-14
ES2528195T3 (es) 2015-02-05
US20040204461A1 (en) 2004-10-14
DK3889142T3 (da) 2022-09-12
US8129540B2 (en) 2012-03-06
US10071081B2 (en) 2018-09-11
ES2926542T3 (es) 2022-10-26
EP4101846A1 (en) 2022-12-14
US20100216851A1 (en) 2010-08-26
HUE031794T2 (en) 2017-08-28
EP1618098B1 (en) 2014-11-19
US9861617B2 (en) 2018-01-09
US8975287B2 (en) 2015-03-10
HK1202254A1 (en) 2015-09-25
US8299105B2 (en) 2012-10-30
PL3345895T3 (pl) 2020-05-18
ES2679108T3 (es) 2018-08-22
CR8086A (es) 2006-12-19
US6992096B2 (en) 2006-01-31
AU2004229487A1 (en) 2004-10-28
SI1618098T1 (sl) 2015-04-30
HK1093979A1 (en) 2007-03-16

Similar Documents

Publication Publication Date Title
NO2015002I2 (no) Ataluren (3-[5-(2-fluorfenyl)-[ 1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav
HK1090294A1 (en) Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4- oxadiazol-2-yl] phenyl)pyridine-3-sulphonamide and a biphosphonate ;
DK1400518T3 (da) Heterocycliske forbindelser og lægemidler
EP1583750A4 (en) MACROCYCLIC BETA-SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
EP1656359A4 (en) MACROCYCLIC BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER&#39;S DISEASE
NO20033203L (no) Terapeutiske heterocykliske forbindelser
HK1132260A1 (en) 1-(benzo [d] [1,3] di0x0l-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
HRP20080446T3 (en) Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
IS7766A (is) N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíð sem krabbameinslyf
IL172542A0 (en) 2-hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide
ATE290534T1 (de) 4-(oxadiazol-3-yl)-1,4-diazabizyklo(3.2.2)- nonanderivate, ihre herstellung und therapeutische verwendung
DK1674456T3 (da) Nye 1,4-benzothiazepin-1,1-dioxid-derivater med forbedrede egenskaber, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
HK1096960A1 (en) Amidomethyl-substituted 2-(4-sulfonilamino)-3-hidroxy-3,4-dihydro-2h- chromium-6-yl-derivatives and drugs containing said compounds
NO20024520L (no) Heterocyklisk sidekjede-inneholdende, N-substituerte metalloproteaseinhibitorer
DE50001868D1 (de) Herbizide mischung, enthaltend ein 3-heterocyclyl-substituiertes benzoylderivat und ein adjuvant
NO20001391D0 (no) Ívelsesanordning for golfslag
ZA200309513B (en) Novel heterocyclic derivatives and medicinal use thereof.
IS6679A (is) Ný form (R)-N-[5-metýl-8-(4-metýlpíperasín-1-ýl)-1,2,3,4-tetrahýdró-2-naftýl]-4-morfólínóbensamíðs
GB0026578D0 (en) Heterocyclic derivatives useful as pharmaceutical agents
ZA200704104B (en) A combination of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer
NO20043483L (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus
NO20032006L (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
EG22745A (en) 2-(3,5-Disbustituted-4-pyridyl)-4-(thienyl) thiazolyl or arylphenyl)1,30xazoline compounds
WO2001068063A3 (en) Novel use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
DE60112310D1 (de) Das hydrochloridsalz des 5[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dions

Legal Events

Date Code Title Description
MK1K Patent expired